EMA committee recommends Almirall's psoriasis drug

The path is now cleared for Spanish Almirall to sell and market its candidate, lebrikizumab, in Europe for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis.

The EMA advisory panel, CHMP, recommends approving drug candidate lebrikizumab in Europe, which is marketed by Spanish dermatology company Almirall under the trade name, Ebglyss. | Photo: Mikkel Aabenhus Hemmingsen / Medwatch

by ALBERT RØNNING-ANDERSSON

The EMA’s advisory panel, CHMP, recommends approval in Europe of drug candidate lebrikizumab, developed by Spanish dermatology company Almirall, which has been given the trade name Ebglyss, Barcelona-based Almirall writes in a stock exchange announcement on Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Almirall raises EUR 200m in share offering
For subscribers
Almirall expanding in the Nordics – ramps up hiring
For subscribers
Almirall to collaborate with Spanish research center on skin cancer treatment
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Photo: Mike Segar/Reuters/Ritzau Scanpix

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.
For subscribers

FDA rejects atopic dermatitis drug lebrikizumab

Eli Lilly had expected a launch this year.

For subscribers

Scott Thomas Smith, CFO of Ascendis Pharma. | Foto: Ascendis Pharma / Pr

Pharma & biotech

Sale of royalties marks new approach to funding for Ascendis

Ascendis has historically raised capital through share issues, but that way of business is coming to an end.

For subscribers

Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

EMA’s rådgivende panel, CHMP, anbefaler at godkende lægemiddelkandidaten Transcon PTH, som det dansk-amerikanske biotekfirma Ascendis Pharma står bag. | Foto: Kevin Grønnemann / Medwatch

Pharma & biotech

EMA committee recommends drug candidate from Ascendis Pharma

In the US, the FDA rejected the drug candidate TransCon PTH in May, but in Europe, the path now seems clear for the Danish-American biotech company’s hypoparathyroidism drug to be approved.

For subscribers